Compass Financial Management LLC Acquires New Stake in Omeros Corporation $OMER

Compass Financial Management LLC acquired a new stake in Omeros Corporation (NASDAQ:OMER) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 32,815 shares of the biopharmaceutical company’s stock, valued at approximately $312,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Ancora Advisors LLC grew its position in shares of Omeros by 46.7% in the 2nd quarter. Ancora Advisors LLC now owns 168,750 shares of the biopharmaceutical company’s stock worth $1,605,000 after acquiring an additional 53,750 shares in the last quarter. Two Sigma Securities LLC acquired a new stake in shares of Omeros during the second quarter worth $152,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Omeros by 9,655.4% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 53,362 shares of the biopharmaceutical company’s stock worth $507,000 after purchasing an additional 52,815 shares during the period. Wellington Management Group LLP lifted its position in shares of Omeros by 9.2% in the 2nd quarter. Wellington Management Group LLP now owns 204,541 shares of the biopharmaceutical company’s stock worth $1,945,000 after buying an additional 17,241 shares during the last quarter. Finally, Corient Private Wealth LP acquired a new stake in Omeros during the second quarter worth about $6,274,000. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Omeros

In other Omeros news, Director Thomas J. Cable sold 15,000 shares of Omeros stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $18.45, for a total value of $276,750.00. Following the completion of the sale, the director directly owned 35,067 shares in the company, valued at $646,986.15. The trade was a 29.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Peter B. Cancelmo sold 25,000 shares of the stock in a transaction on Monday, August 31st. The stock was sold at an average price of $18.54, for a total transaction of $463,500.00. Following the transaction, the vice president owned 200 shares in the company, valued at approximately $3,708. This trade represents a 99.21% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 105,906 shares of company stock valued at $1,989,705 in the last quarter. Corporate insiders own 10.50% of the company’s stock.

Omeros Stock Performance

Shares of OMER stock traded down $0.05 during trading on Tuesday, hitting $19.38. 392,591 shares of the company were exchanged, compared to its average volume of 1,687,282. The business’s 50-day simple moving average is $16.40 and its 200 day simple moving average is $13.11. Omeros Corporation has a twelve month low of $4.05 and a twelve month high of $21.24. The firm has a market capitalization of $1.40 billion, a price-to-earnings ratio of 15.14 and a beta of 2.60.

Omeros (NASDAQ:OMER) last released its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.29. The firm had revenue of $28.53 million for the quarter, compared to analyst estimates of $12.69 million. On average, equities analysts forecast that Omeros Corporation will post -0.37 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Zacks Research cut Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. HC Wainwright reissued a “buy” rating on shares of Omeros in a report on Monday, July 27th. Weiss Ratings lowered shares of Omeros from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, September 22nd. Wall Street Zen upgraded shares of Omeros from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. Finally, Cantor Fitzgerald upgraded Omeros from a “neutral” rating to an “overweight” rating and set a $22.00 price objective for the company in a research report on Tuesday, September 22nd. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $34.00.

About Omeros

Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994.

Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.